Works matching IS 17762596 AND DT 2022 AND VI 17 AND IP 4
Results: 10
Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 4, p. 483, doi. 10.1007/s11523-022-00898-7
- By:
- Publication type:
- Article
What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 4, p. 383, doi. 10.1007/s11523-022-00897-8
- By:
- Publication type:
- Article
Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Author's Reply to Şener and Begijanashvili: "Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy".
- Published in:
- 2022
- By:
- Publication type:
- Letter
Comment on: "Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy".
- Published in:
- 2022
- By:
- Publication type:
- Letter
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 4, p. 433, doi. 10.1007/s11523-022-00893-y
- By:
- Publication type:
- Article
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 4, p. 467, doi. 10.1007/s11523-022-00892-z
- By:
- Publication type:
- Article
Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 4, p. 453, doi. 10.1007/s11523-022-00889-8
- By:
- Publication type:
- Article